Investigation on Advanced Non-Small-Cell Lung Cancer among Elderly Patients Treated with Chinese Herbal Medicine versus Chemotherapy: A Pooled Analysis of Individual Data

Table 2

Patient characteristics at baseline.

	CT	CHM	P-value
	(n=224)	(n=262)
Gender			0.001
Male	171 (76.3%)	164 (62.6%)
Female	53 (23.6%)	98 (37.4%)
Age (continuous)			0.002
Mean ± SD	67.9 ± 5.6	69.6 ± 5.9
Age (categorical)			0.001
⩽70	154 (68.8%)	143 (54.6%)
>70	70 (31.2%)	119 (45.2%)
Smoking Status			0.087
Missing	3 (1.3%)	0 (0.0%)
Non-smokers	108 (48.2%)	142 (54.2%)
Smokers	113 (50.4%)	120 (45.8%)
Tumor Location			0.535
Missing	42 (18.8%)	45 (17.2%)
Central Type	59 (26.3%)	81 (30.9%)
Peripheral Type	123(54.9%)	136(51.9%)
Pathology			0.537
Non-SQCC	104 (46.4%)	129 (49.2%)
SQCC	120 (53.6%)	133 (50.8%)
Stage			0.082
III	67 (29.9%)	98 (37.4%)
IV	157 (70.1%)	164 (62.6%)
Previous Treatment			0.014
No	150 (66.8%)	147 (56.1%)
Yes	74 (33.0%)	115 (43.9%)
KPS			0.216
60	20 (8.9%)	32 (12.2%)
70	61 (27.2%)	56 (21.4%)
⩾80	143 (63.8%)	174 (66.4%)
Clinical Study			0.655
1	50 (22.3%)	65 (24.8%)
2	131 (58.5%)	154 (58.8%)
3	43 (19.2%)	43 (16.4%)
Follow Up Period
Median (95% CI)	550 (448, 599)	450(384, 561)	0.705
Status			0.629
Alive	55 (24.6%)	65 (24.8%)
Died	146 (65.2%)	163 (62.2%)
Lost to Follow Up	23 (10.3%)	34 (13.0%)

Note: SQCC, squamous cell carcinoma; KPS, Karnofsky performance scores; CHM, Chinese herbal medicine; CT, chemotherapy; SD, standard deviations. a: log rank test.